Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 7 Pheochromocytoma 2 Paraganglioma 2 Gastro-enteropancreatic neuroendocrine tumor 2 Vipoma 1 Thymus Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Meningioma 1 Insulinoma 1 Gastrinoma 1 Carcinoma, Merkel Cell 1 Carcinoid Tumor 1

Interventions

Surveys and Questionnaires 114 Exercise 103 Blood Specimen Collection 99 Radiotherapy 67 Gemcitabine 64 Bevacizumab 57 Standard of Care 56 Cisplatin 55 Cyclophosphamide 51 Capecitabine 50 Carboplatin 49 Docetaxel 47 pembrolizumab 46 Dexamethasone 46 Paclitaxel 45 Interviews as Topic 43 Oxaliplatin 40 Magnetic Resonance Spectroscopy 39 Fluorouracil 37 Methods 36 Irinotecan 36 Therapeutics 33 Drug Therapy 33 Radiosurgery 31 Nivolumab 30 Erlotinib Hydrochloride 27 Educational Status 26 Everolimus 24 Leucovorin 23 Control Groups 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all

NCT04997317 2025-04-13

PROMENADE

University Hospital, Basel, Switzerland

Phase 1/2 Recruiting

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡